Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boots pharmacies to open for longer
The drugstore has already switched to the longer opening hours at eight of its stores; the two most recent changes being made in Oxford and Milton Keynes at
The drugstore has already switched to the longer opening hours at eight of its stores; the two most recent changes being made in Oxford and Milton Keynes at
The alliance combines Sirna’s extensive expertise in short interfering RNA (siRNA) chemistry and biology with GSK’s industry leading capabilities in the development and commercialization of novel therapies for
The findings, reported at the annual meeting of the American Association for Cancer Research (AACR), were made in cell culture and mice studies, but are so promising that
The new institute will focus on major brain and mind disorders including stroke, epilepsy, multiple sclerosis, dementia, Parkinson’s disease, addiction, schizophrenia and mood disorders. As part of the
Erbitux is already licensed in 53 countries for metastatic colorectal cancer after failure of irinotecan-based chemotherapy. With the European Commission’s approval, Erbitux will be available for the treatment
According to the company, Zestra is the only consumer product available that is clinically shown to quickly increase female sexual sensation, arousal, pleasure, and improve sexual experiences for
This phase I, dose-escalation trial of GRN163L is primarily designed to demonstrate the safety and tolerability of GRN163L administered intravenously (IV) on a weekly basis in patients with
The second phase III trial will involve approximately 630 patients in a randomized, double-blind multi-centre trial comparing Urocidin to bacillus calmette-guerin (BCG) as first-line therapy in non-muscle invasive
This new formulation, Actoplus met XR, would allow for once-daily dosing. The immediate release formulation of the drug is already being marketed by Takeda Pharmaceuticals North America. Actoplus
In this placebo-controlled analysis, approximately two-thirds of patients who received 8mg of Rozerem experienced at least a 50% reduction in the time it took them to fall asleep.